Showing posts with label laser. Show all posts
Showing posts with label laser. Show all posts

Wednesday, February 23, 2011

Lasers ID Deadly Skin Cancer Better than Doctors

High-resolution images from a laser-based tool developed at Duke University could help doctors better diagnose melanoma, the deadliest form of skin cancer.

The improved diagnoses could potentially save thousands of lives and millions of dollars in unnecessary healthcare costs each year.

The tool probes skin cells using two lasers to pump small amounts of energy, less than that of a laser pointer, into a suspicious mole. Scientists analyze the way the energy redistributes in the skin cells to pinpoint the microscopic locations of different skin pigments.

For the first time, scientists have the ability to identify substantial chemical differences between cancerous and healthy skin tissues, said Thomas Matthews, a Duke graduate student who helped develop the new two-laser microscopy technique.

The Duke team imaged 42 skin slices with the new tool. The images show that melanomas tend to have more eumelanin, a kind of skin pigment, than healthy tissue. Using the amount of eumelanin as a diagnostic criterion, the team used the tool to correctly identify all eleven melanoma samples in the study. The results appear in the Feb. 23 Science Translational Medicine.

The technique will be further tested using thousands of archived skin slices. Studying old samples will verify whether the new technique can identify changes in moles that eventually did become cancerous.

Even if the technique proves, on a large scale, to be 50 percent more accurate than a biopsy, it would prevent about 100,000 false melanoma diagnoses, said Warren S. Warren, director of Duke’s Center for Molecular and Biomolecular Imaging and a chemistry professor. Warren oversaw the development of the new melanoma diagnostic tool.

cancertissueWarren's group has succeeded in using the laser pump method to locate two different types of skin pigments in skin tissue, which may better identify developing melanoma, said James Grichnik, a dermatologist at the University of Miami who was not involved in the study.

The work is limited to fixed tissue on slides, but holds promise for diagnosing melanoma prior to biopsy, and the increased diagnostic accuracy, without unnecessary biopsies, is where the new tool could have cost-saving potential, he said.

Melanoma is the fifth-most common cancer for males and sixth-most common for females. In 2010, U.S. doctors diagnosed nearly 115,000 new cases of the disease, with nearly 8,700 resulting in death. The cancer is also one of the few where the death rate is increasing.

Doctors typically use a light and a magnifying glass or tissue biopsy, where a pathologist removes suspicious skin cells and looks at them under a microscope, to spot signs of disease. But using a lens and a light is a “17th century” technique that is only 85 percent accurate, at best, and tissue biopsy is not much more reliable, Warren said.

In 14 percent of biopsy diagnoses, pathologists would disagree on whether or not the sampled cells were cancerous, according to a 2010 study published in the Journal of American Academy of Dermatology. The statistic implies that two pathologists would have opposing diagnoses on 214,000 to 643,000 melanoma cases each year, Warren said.

When studying biopsied tissue, doctors typically follow the “when in doubt, cut it out” philosophy. If they are not sure about the health of the skin tissue, doctors remove additional skin around the diseased cells. The first and second tissue biopsies can cost thousands of dollars. If the melanoma is thought have spread, patients may then have lymph nodes in their arms removed or undergo chemotherapy, which dramatically adds to treatment costs.

But not all of the extra treatment is necessary because not all of the biopsied tissues are actually cancerous. Doctors need a more accurate way to diagnose melanoma, Warren said.

In 2009, he received a $1 million Challenge Grant from the National Institutes of Health, which was part of the American Recovery and Reinvestment Act of 2009, to develop the imaging tool.

The highly specialized lasers are currently commercially available and would only need to be added to the microscopes pathologists already use to diagnose melanomas. The cost for the added instrumentation is about $100,000, which may sound like a lot of money. But if each false positive melanoma diagnosis costs thousands of dollars, having such an instrument available for questionable cases could considerably reduce health care costs overall, Warren said.

He added that suspicious moles would still have to be removed from a patient and then imaged to detect cancer.

Matthews is working on imaging skin cancers grafted on to mice to see if the tool could become a device dermatologists could use to scan a mole without removing it. A device like that would be much more expensive and would not be ready for a few years, Warren said. However, pathologists could begin using the lasers to study biopsied tissue now.

-----
Community News You Can Use
Click to read MORE news:
www.GeorgiaFrontPage.com
Twitter: @gafrontpage & @TheGATable @HookedonHistory
www.ArtsAcrossGeorgia.com
Twitter: @artsacrossga, @softnblue, @RimbomboAAG @FayetteFP

Wednesday, May 14, 2008

Fastest Minimally-Invasive In-Office biolitec Laser Treatment for BPH Hailed by AUA Surgeons as Most Effective, with Lowest Costs

BUSINESS WIRE--Three leading urological surgeons reporting to groups of peer doctors this Saturday, May 17 at the 2008 American Urological Association’s National Scientific meeting disclosed their highly successful results involving their first biolitec-produced high-power EVOLVE® laser treatments with U.S. BPH patients. Patients, with benign prostate hyperplasia, or enlarged prostate, were treated with the latest minimally-invasive laser techniques performed in office settings, reducing procedures to less than 10 minutes time while avoiding expensive overnight hospital stays and deductibles.

Key to the successful new treatment is the recently cleared 150-watt EVOLVE diode laser, demonstrated at this week’s meeting. Beyond shortening treatment times and facilitating vaporization and coagulation (tissue removal without strong bleeding), the new technique offers minimal side effects and fastest recovery times.

According to biolitec, the new high-power 150-watt laser, which has been shipping to various U.S. urology facilities since January 1, is experiencing strong growth and is expected to surge considerably beyond EVOLVE laser systems’ current 20 percent U.S. market penetration.

The laser’s high power reduces treatment time for ablating the prostatic tissue that causes obstruction in urine flow. In-office ambulatory treatment under local anesthesia is simple and fast, with patients remaining fully conscious.

Significance of this new treatment option is heightened by the high incidence of BPH in one of every two men over age 60, and in nearly every U.S. male 80 and older. No hospitalization is required and patients out-of-pocket cost is typically an office co-pay.

Professionals attending this week’s AUA conference heard actual experiential case data from Mark Swierzewski, MD, of Tampa Bay Urology, in Florida, James Ulchaker, MD, of Cleveland Clinic, David S. Turk, MD, Southwest Urology, Cleveland, (who previously received AUA’s 2007 Thirlby Award for presenting his earliest successes with the technique) and Ali Erol, MD, Duzce University, Istanbul, Turkey.

Other competitive laser options differences are in design, wavelength, power levels, anesthesia and treatment settings. The new treatment can now be offered in a gentle manner on an out-patient basis at any clinic or urology practice, without expensive anesthesia.